Fidelity Investments’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Fidelity Investments’s Portfolio CYT Stock Details CYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-826,758	Closed	-$2.35M	–	5708
2023 Q3	$2.35M	Sell	826,758 -1,109	-0.1%	-$3.06K	﹤0.01%	2247
2023 Q2	$2.15M	Sell	827,867 -1,424,464	-63%	-$2.98M	﹤0.01%	2295
2023 Q1	$4.1M	Sell	2,252,331 -656,045	-23%	-$1.07M	﹤0.01%	2151
2022 Q4	$4.8M	Sell	2,908,376 -577,682	-17%	-$927K	﹤0.01%	2140
2022 Q3	$6.69M	Sell	3,486,058 -386,231	-10%	-$1.01M	﹤0.01%	2069
2022 Q2	$11.6M	Sell	3,872,289 -628,944	-14%	-$1.61M	﹤0.01%	1899
2022 Q1	$17M	Buy	4,501,233 +452,240	+11%	+$2.57M	﹤0.01%	1857
2021 Q4	$46M	Sell	4,048,993 -236,666	-6%	-$3.61M	﹤0.01%	1456
2021 Q3	$75.2M	Buy	4,285,659 +3,225,453	+304%	+$60.3M	0.01%	1236
2021 Q2	$22.7M	Buy	+1,060,206	New	+$19.9M	﹤0.01%	1801

Other funds holding CYT

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Bulldog Investors Saddle Brook, New Jersey $455M AUM 2.3% 1-Year Est. Return

Fidelity Investments's CYT Position: Q4 2023 in Review

Fidelity Investments sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q4 2023, closing a stake of 826,758 shares — an estimated $2.35M sold.

Fidelity Investments first reported a position in CYT in Q2 2021 and held it in 10 quarters. The position peaked at $75.2M in Q3 2021. 38 funds tracked by Wall St. Rank hold CYT as of Q4 2023.

Fidelity Investments reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Fidelity Investments sold 826,758 Cyteir Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $2.35M.
Fidelity Investments first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 10 quarters.
Fidelity Investments's Cyteir Therapeutics, Inc. Common Stock position peaked at $75.2M in Q3 2021.
38 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Fidelity Investments's 13F filing for Q4 2023, filed 13 Feb 2024.